Avalyn Pharma Inc. Common Stock
NASDAQ:AVLNMedical - Pharmaceuticals
+$0.52 today
- Market cap
- $1.23B
- Beta
- 0.00
Volume 0.40M
Average 0.51M
AVLN Cost of Revenue
Direct costs of producing the goods and services sold, such as materials, manufacturing, and service delivery.
Cost of Revenue history
Currency unavailable · from the income statement
No Cost of Revenue data reported for this period type.
Cost of Revenue vs competitors
How AVLN compares with its peers on the latest reported figures
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Jun 2026 | $190.3M USD | +96.8% | +31.3% | 16.7% | |
| LTM Mar 2026 | $86.73M USD | +14.8% | +2.1% | 24.0% | |
| LTM Mar 2026 | $5.75M USD | +51.3% | +4.2% | 4.9% | |
VCREVicore Pharma Holding AB | LTM Jun 2026 | SEK 0 SEK | -100.0% | — | 0.0% |
AVLNAvalyn Pharma Inc. Common Stock | — | — | — | — | — |
| Peer median (excluding AVLN) | — | +33.1% | +4.2% | 10.8% | |
Competitors are the stored peer set for AVLN. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Avalyn Pharma Inc. Common Stock
NASDAQ:AVLN
Intrinsic Alpha fair value
Locked
Current Price
$27.69
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.